Azure

Specialisation

Retina and Vitreous.

Full title

Randomised, active-controlled, parallel group, phase III trial on the efficacy, safety and tolerability of 2 mg aflibercept administered with intyravidial injections using two different regimens of treatment for subjects with neovascular age-related macular degeneration.

Promoter

Bayer.

Start date

January 2016.

Researchers

Principal: Dr Anniken Burés.